The North American anticoagulants market is estimated to grow at a CAGR of 7.2% during the forecast period. An increasing approval for anticoagulants has been witnessed in the US owing to the rising incidences of heart diseases. The emerging focus on launches of generics has also been reported in the region. For instance, in June 2020, Gland Pharma Ltd. and its collaborators Athenex Pharmaceutical Division and MAIA Pharmaceuticals Inc. declared the US introduction of a ready-to-use Bivalirudin injection. It is an anticoagulant indicated for the treatment of patients who are experiencing percutaneous coronary intervention (PCI). This comprises patients suffering from heparin-induced thrombocytopenia, thrombosis syndrome, and heparin-induced thrombocytopenia.
(Get 15% Discount on Buying this Report)
A full report of North American Anticoagulants Market is available at: https://www.omrglobal.com/industry-reports/north-american-anticoagulants-market
Additionally, in December 2019, the US FDA approved two applications for the first generics of Eliquis (apixaban) tablets. These medications are intended to minimize the chances of systemic embolism and stroke in patients who are suffering from nonvalvular atrial fibrillation. The approval of the generic apixaban is granted to Micro Labs Ltd. and Mylan Pharmaceuticals Inc. The approval of these new drugs is supporting to increase the safety and efficacy of anticoagulants, which in turn, will further accelerate the market growth.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-anticoagulants-market
Scope of the North American Anticoagulants Market
Market Coverage
- The market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type and Application
- Countries Covered- US and Canada
- Competitive Landscape- Johnson & Johnson Services, Inc., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH
Recent Strategic Initiatives in the North American Anticoagulants Market
- In October 2020, Janssen declared that it submitted a supplemental New Drug Application (sNDA) to the FDA to increase the XARELTO application for peripheral artery disease (PAD) patients to comprise decreasing the risk of major thrombotic vascular events, including amputation and heart attack, in symptomatic patients after recent lower-extremity revascularization (LER). It is currently approved to decrease the risk of major CVD events in patients with chronic PAD or coronary artery disease (CAD).
- In January 2019, AMAG Pharmaceuticals, Inc. acquired Perosphere Pharmaceuticals Inc., a biopharmaceutical firm. With this acquisition, AMAG will include ciraparantag to its drug development portfolio. It is in development for application in patients treated with low molecular weight heparin (LMWH) or novel oral anticoagulants (NOACs).
Key questions addressed by the report
- What is the market growth rate?
- Which segment dominates the market in the base year?
- Which segment will project the fastest growth in the market?
- How COVID-19 impacted the market?
- Recovery Timeline
- Deviation from the pre-COVID-19forecast
- Most affected segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
North American Anticoagulants Market-Segmentation
By Type
- Novel Oral Anticoagulants (NOACs)
- Vitamin K Antagonist
- Heparin and Low Molecular Weight Heparin (LMWH)
By Application
- Pulmonary Embolism
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
